Table 3. Univariate analysis of the impact of anthropometric, molecular and metabolic determinants on survival in endocrine sensitive (N:97) and endocrine resistant (N:64) patients HR+ metastatic breast cancer patients treated with fulvestrant.
| Variables | Median 1PFS (95% 3CI) | Median 2OS (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|
| Endocrine Sensitivity | Endocrine Sensitivity | |||||||
| No N: 64 |
p | Yes N: 97 |
p | No N: 64 |
p | Yes N: 97 |
p | |
|
4BMI <25 >=25 |
7(6-7) 5(4-7) |
0.01 |
7(5-9) 8(4-12) |
0.10 |
35(15-55) 22(16-27) |
0.36 |
23(2-44) 52(26-78) |
0.05 |
|
5HER2 Pos Neg |
6(5-7) 5(3-6) |
0.87 |
6 (0-17) 8(6-9) |
0.60 |
12(7-17) 30(19-42) |
0.03 |
n.r. 40(20-61) |
0.32 |
|
Age >=65 <65 |
6(4-7) 6(5-7) |
0.40 |
8(7-10) 6(3-8) |
0.05 |
24(12-35) 25(9-41) |
0.97 |
n.a. 52(8-95) |
0.09 |
|
6ER% >=30 <30 |
6(5-7) n.a. |
n.a. |
8(6-9) 4 (3-5) |
0.86 |
24(13-34) n.a. |
40(25-55) n.a. |
0.24 |
|
|
7PgR Neg Pos |
6(0-13) 6 (5-8) |
0.77 |
n.a. 8(6-9) |
0.15 |
n.a. 24(12-35) |
0.68 |
n.a. 41(23-59) |
0.28 |
|
Ki67% <15 >=15 |
6mesi (4-9) 6mesi (4-7) |
0.73 |
7(5-8) 11(3-18) |
0.074 |
21(17-26) 30(17-44) |
0.41 |
41(19-63) n.a. |
0.93 |
|
Fulvestrant in 1st/subsequent line: 1 ≥2 |
7(5-8) 5(4-6) |
0.09 |
10(6-15) 7(4-9) |
0.01 |
32(19-44) 19(9-29) |
0.03 |
n.r. 29(8-50) |
0.17 |
|
N metastatic sites 1 >1 |
6 (5-7) 5(4-6) |
0.85 |
10(2-18) 7(4-10) |
0.003 |
35(22-49) 22(10-33) |
0.11 |
n.a. 25(16-34) |
0.008 |
|
Visceral Involvement Yes No |
6 (5-8) 5 (3-7) |
0.69 |
6(2-10) 9(3-15) |
0.01 |
32(22-42) 19(8-30) |
0.19 |
40(12-68) n.a. |
0.09 |